Educational reference only — not medical advice. Nothing is sold on this site. Research compounds are not for human use.
Home>>Peptides>>Adipotide (FTPP)
PreclinicalGH / growth factors

Adipotide (FTPP)

An experimental peptidomimetic designed to bind prohibitin receptors on white-adipose blood vessels and trigger their regression — an approach to fat loss through vascular targeting.

CompoundAdipotide (FTPP)
CategoryVasculature-targeting peptidomimetic
ClassGrowth Hormone and Growth Factors
Evidence tierPreclinical
WADA statusNot individually listed; verify current status if subject to testing
Sold on this siteNo — this is a reference database

Overview

Adipotide (FTPP) is catalogued here as a vasculature-targeting peptidomimetic and graded at the "Preclinical" evidence tier. The evidence base for this compound is dominated by animal and cell-culture studies. Mechanism may be plausible; human benefit and safety are unestablished.

An experimental peptidomimetic designed to bind prohibitin receptors on white-adipose blood vessels and trigger their regression — an approach to fat loss through vascular targeting.

Mechanism of Action

Adipotide homes to prohibitin-expressing adipose vasculature, inducing endothelial apoptosis, loss of blood supply, and resorption of fat tissue.

Research and Evidence

Primate studies reported substantial fat loss — accompanied by kidney toxicity signals that exemplify the approach’s risks. Human trials were never conducted.

Evidence in context: the Growth Hormone and Growth Factors class page collects the shared evidence themes and study-reading guidance for this category.

Safety and Side Effects

Renal adverse effects in animal studies halted development; no human safety data.

Educational notice: this entry describes published research and, where they exist, regulator labels. It is not medical advice and not a recommendation for use. Research-grade compounds have no verified human-safety data.

Frequently Asked Questions

What is the evidence tier of Adipotide (FTPP)?

Adipotide (FTPP) is graded "Preclinical" on this site. The evidence base for this compound is dominated by animal and cell-culture studies. Mechanism may be plausible; human benefit and safety are unestablished.

Is Adipotide (FTPP) an approved medicine?

No. Preclinical means the compound has not reached universal regulatory approval; the tier description above explains exactly what level of evidence exists.

Where can I read the primary studies for Adipotide (FTPP)?

The references section at the end of this entry links the key primary sources — regulator labels, trial registrations, and peer-reviewed papers. Our "How to Read a Peptide Study" guide explains how to evaluate them.

References

  1. ClinicalTrials.gov — search for adipotide studies (none registered). [source]
EM
Dr. Elena Marsh, PhDMolecular Pharmacology · Lead Editor

Written and maintained by the editorial team. Medically reviewed by Dr. James Okafor, MD (Internal Medicine).

Evidence tier: Preclinical · Last reviewed: 2026-09-05 · Sources cited below.

Advertisement